1. Home
  2. VRNA vs SRAD Comparison

VRNA vs SRAD Comparison

Compare VRNA & SRAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRNA
  • SRAD
  • Stock Information
  • Founded
  • VRNA 2005
  • SRAD 2001
  • Country
  • VRNA United Kingdom
  • SRAD Switzerland
  • Employees
  • VRNA N/A
  • SRAD N/A
  • Industry
  • VRNA Biotechnology: Pharmaceutical Preparations
  • SRAD Computer Software: Programming Data Processing
  • Sector
  • VRNA Health Care
  • SRAD Technology
  • Exchange
  • VRNA Nasdaq
  • SRAD Nasdaq
  • Market Cap
  • VRNA 8.3B
  • SRAD 7.7B
  • IPO Year
  • VRNA 2017
  • SRAD 2021
  • Fundamental
  • Price
  • VRNA $104.83
  • SRAD $28.76
  • Analyst Decision
  • VRNA Buy
  • SRAD Strong Buy
  • Analyst Count
  • VRNA 11
  • SRAD 15
  • Target Price
  • VRNA $112.40
  • SRAD $27.40
  • AVG Volume (30 Days)
  • VRNA 5.5M
  • SRAD 2.0M
  • Earning Date
  • VRNA 08-07-2025
  • SRAD 08-12-2025
  • Dividend Yield
  • VRNA N/A
  • SRAD N/A
  • EPS Growth
  • VRNA N/A
  • SRAD 114.88
  • EPS
  • VRNA N/A
  • SRAD 0.20
  • Revenue
  • VRNA $118,535,000.00
  • SRAD $1,245,020,536.00
  • Revenue This Year
  • VRNA $891.79
  • SRAD $17.66
  • Revenue Next Year
  • VRNA $78.94
  • SRAD $15.21
  • P/E Ratio
  • VRNA N/A
  • SRAD $143.33
  • Revenue Growth
  • VRNA N/A
  • SRAD 23.07
  • 52 Week Low
  • VRNA $17.96
  • SRAD $10.06
  • 52 Week High
  • VRNA $104.99
  • SRAD $29.73
  • Technical
  • Relative Strength Index (RSI)
  • VRNA 70.87
  • SRAD 70.83
  • Support Level
  • VRNA $86.63
  • SRAD $27.73
  • Resistance Level
  • VRNA $104.99
  • SRAD $29.73
  • Average True Range (ATR)
  • VRNA 2.73
  • SRAD 0.90
  • MACD
  • VRNA 0.50
  • SRAD 0.12
  • Stochastic Oscillator
  • VRNA 99.24
  • SRAD 80.48

About VRNA Verona Pharma plc

Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.

About SRAD Sportradar Group AG

Sportradar Group AG is a technology platform enabling next-generation engagement in sports, and a provider of B2B solutions to the sports betting industry. It generates revenue through two primary sources: subscription-based revenue and revenue sharing. Geographically, it operates in North America, Africa, AsiaPac & Middle East, Europe, and LATAM & Caribbean.

Share on Social Networks: